EFX Stock Movement Summary Equifax (EFX) drifted lower on light volume amid ongoing regulatory scrutiny. Three Democratic senators—Elizabeth Warren, Ron Wyden, and Bernie Sanders—accused Equifax of price gouging states for "The Work Number," a service used to verify Medicaid applicants' wages and work hours. This service will become critical for states complying with new Medicaid work requirements effective January 1, 2027. Despite these headwinds, Equifax reported Q4 2025 results on February 4, with revenue climbing 9% year-over-year to $1.55 billion, exceeding guidance. However, analysts subsequently cut forecasts following the earnings report. The stock has declined 18% over the past 30 days and 32.47% over the past year. The average 12-month analyst price target is $262.0, representing a 5.48% decrease from the previous average.
Read full analysisEFX Stock Movement Summary Equifax (EFX) drifted lower on light volume amid ongoing regulatory scrutiny. Three Democratic senators—Elizabeth Warren, Ron Wyden, and Bernie Sanders—accused Equifax of price gouging states for "The Work Number," a service used to verify Medicaid applicants' wages and work hours. This service will become critical for states complying with new Medicaid work requirements effective January 1, 2027. Despite these headwinds, Equifax reported Q4 2025 results on February 4, with revenue climbing 9% year-over-year to $1.55 billion, exceeding guidance. However, analysts subsequently cut forecasts following the earnings report. The stock has declined 18% over the past 30 days and 32.47% over the past year. The average 12-month analyst price target is $262.0, representing a 5.48% decrease from the previous average.
Equifax Inc. (EFX) is a publicly traded company in the Broad Market sector.